The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.

New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.

New Rogel and Blondy Center for Pancreatic Cancer will bring together researchers and clinicians to drive forward new treatments and improve outcomes

In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it

Researchers have developed a new model to help predict treatment response in patients with bladder cancer. 

A study finds that efforts to cap prescription drug spending are yielding significant out-of-pocket savings for these patients.

Researchers have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development.

As cancer treatment and survivorship care relies more on understanding the genetic make up of an individual’s tumor, a study from the University of Michigan Health Rogel Cancer Center finds that many breast cancer survivors who meet criteria for genetic counseling and testing are not receiving it.

Researchers find common immune system mechanism between pregnancy, cancer

Changing how often a popular cancer therapy is delivered would reduce greenhouse gas emissions and improve environmental impact without decreasing cancer survival, according to a new analysis from researchers at the University of Michigan Health Rogel Cancer Center.

A new urine-based test helps men avoid unnecessary biopsies and addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Socially vulnerable patients were more likely to stick with oral medications when treated at a hospital participating in 340B program, suggesting these hospitals may have more resources to help patients.

Model shows how oncostreams form and behave in brain tumors – and how to inhibit them

Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.

Founding Rogel Cancer Center Director reflects on how cancer evolved from ‘the least scientific discipline’ to a shining example of how basic research discoveries can change clinical care.